Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:52:46.967Z.
Calculation as of: 2026-10-06T16:52:46.967Z.
Quote observation: 2026-10-06T16:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 41380868948bde6df6f28b5310a55e7ea83c2eaa443efb93c39b202ec723f694
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Processa Pharmaceuticals, Inc.
Market Cap
$4.10M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.19M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.25M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.85M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.40M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.43M
Operating Cash Flow Yield
N/A
TTM Avg
3.14%
3Y Avg
3.14%
5Y Avg
3.14%
Market Cap
$4.52M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.10M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.19M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.00M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.25M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.85M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | N/A | 3.14% | 3.14% | 3.14% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.52M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.58M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
